Quarterly ResultAug 6, 2026, 04:23 PM
Organogenesis Q2 Revenue Down 58% to $42.8M; Net Loss $96.3M
AI Summary
Organogenesis Holdings Inc. reported a significant decline in its second quarter 2026 financial results, with net revenue decreasing 58% to $42.8 million and net loss widening to $96.3 million. The company also updated its full-year 2026 net revenue guidance, expecting a decline of 62% to 68% year-over-year, reflecting a slower pace of recovery than previously anticipated. Despite the challenging market, the company's CEO noted signs of measured improvement and an expanding market share.
Key Highlights
- Net revenue for Q2 2026 decreased 58% to $42.8 million from $100.8 million in Q2 2025.
- Net loss for Q2 2026 increased to $96.3 million from $9.4 million in Q2 2025.
- Adjusted EBITDA loss for Q2 2026 was $34.4 million, up from $3.6 million in Q2 2025.
- Advanced Wound Care revenue decreased 61% to $36.1 million in Q2 2026.
- Surgical & Sports Medicine revenue decreased 18% to $6.7 million in Q2 2026.
- FY 2026 net revenue guidance updated to $179.0M-$215.0M, a 62%-68% decline YoY.
- Cash, cash equivalents, and restricted cash were $46.8 million as of June 30, 2026.
Price Impact
More from ORGO